



Macronutrient Intake–Associated *FGF21* Genotype Modifies Effects of Weight-Loss Diets on 2-Year Changes of Central Adiposity and Body Composition: The POUNDS Lost Trial

Diabetes Care 2016;39:1909–1914 | DOI: 10.2337/dc16-1111

Yoriko Heianza,¹ Wenjie Ma,² Tao Huang,³
Tiange Wang,¹ Yan Zheng,⁴
Steven R. Smith,⁵ George A. Bray,⁶
Frank M. Sacks,⁴ and Lu Qi^{1,2,4,7}

OBJECTIVE

Fibroblast growth factor 21 (*FGF21*) is involved in the regulation of energy balance and adipose metabolism. Our previous genome-wide association study identified genetic variants in the *FGF21* region associated with macronutrient intake preference. We investigated whether the *FGF21* genotype modified effects of weight-loss diets varying in macronutrient intake on changes in adiposity in a 2-year randomized diet intervention trial.

RESEARCH DESIGN AND METHODS

We genotyped *FGF21* rs838147 in 715 overweight or obese individuals who were assigned to one of four diets varying in macronutrient contents. A DEXA scan was performed to evaluate body composition.

RESULTS

We observed a significant interaction between the *FGF21* genotype and carbohydrate/fat intake on 2-year changes in waist circumference (WC), percentage of total fat mass, and percentage of trunk fat ($P = 0.049$, $P = 0.001$, and $P = 0.003$ for interaction, respectively). In response to the low-carbohydrate/high-fat diet, carrying the carbohydrate intake–decreasing C allele of rs838147 was marginally associated with less reduction in WC ($P = 0.08$) and significantly associated with less reduction of total fat mass ($P = 0.01$) and trunk fat ($P = 0.02$). Opposite genetic associations with these outcomes were observed among the high-carbohydrate/low-fat diet group; carrying the C allele was associated with a greater reduction of WC, total body fat mass, and trunk fat.

CONCLUSIONS

Our data suggest that *FGF21* genotypes may interact with dietary carbohydrate/fat intake on changes in central adiposity and body fat composition. A low-calorie, high-carbohydrate/low-fat diet was beneficial for overweight or obese individuals carrying the carbohydrate intake–decreasing allele of the *FGF21* variant to improve body composition and abdominal obesity.

¹Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA

²Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA

³Epidemiology Domain, Saw Swee Hock School of Public Health and Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

⁴Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA

⁵Florida Hospital and Sanford-Burnham Institute, Orlando, FL

⁶Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA

⁷Channing Laboratory, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

Corresponding author: Lu Qi, lqi1@tulane.edu.

Received 21 May 2016 and accepted 12 August 2016.

Clinical trial reg. no. NCT00072995, clinicaltrials.gov.

This article is featured in a podcast available at <http://www.diabetesjournals.org/content/diabetes-core-update-podcasts>.

© 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <http://www.diabetesjournals.org/content/license>.

See accompanying articles, pp. 1854, 1858, 1870, 1874, 1879, 1889, 1896, 1902, and 1915.

Macronutrients, including fat, carbohydrate, and protein, are primary sources of energy and play a central role in determining energy balance, which regulates body fat accumulation and weight reduction (1,2). In our recent genome-wide association studies (GWAS), we identified sequence polymorphisms close to the fibroblast growth factor 21 (*FGF21*) gene that were associated with intakes of macronutrients (3,4). Our studies consistently showed that the genetic variation in the *FGF21* region was associated with carbohydrate or fat intake (3,4). Prior studies reported that circulating levels of *FGF21* increased in response to carbohydrate intake (5,6), and more recent studies provided possible mechanisms for the role of *FGF21* in regulating “sweet taste preference” (7–9).

FGF21 has been attracting great interest as a whole-body metabolic regulator of energy balance and adipose metabolism (10,11) and also as a therapeutic potential for treatment of obesity (10). Several studies found that elevated blood concentrations of *FGF21* were positively correlated with BMI (12–16), waist circumference (WC) (12,14,16,17), fat mass (13,16), or visceral adipose area (18,19), suggesting obesity as a *FGF21*-resistant state (20). A study also showed a significant association between circulating *FGF21* levels and fasting-mediated weight loss in healthy subjects (21).

Although compelling evidence has shown that dietary interventions with modifications of macronutrients may promote weight loss and improve body fat distribution (2,22,23), considerable interindividual variance has long been noted in response to dietary interventions, and genetic variations may at least partly account for such variance. We hypothesized that the macronutrient-associated *FGF21* genotype might modify the effects of dietary interventions varying in macronutrient intakes on changes in adiposity and body composition. The Preventing Overweight Using Novel Dietary Strategies (POUNDS) Lost trial is thus far one of the largest randomized intervention trials comparing diets varying in macronutrients on long-term weight loss (24). In this study, we investigated whether the GWAS-identified macronutrient intake-associated variant in the *FGF21* gene modified effects of weight-loss diets on the improvement of

adiposity and body composition in the POUNDS Lost trial.

RESEARCH DESIGN AND METHODS

Study Participants

The POUNDS Lost trial was conducted from October 2004 through December 2007 at two sites: Harvard T.H. Chan School of Public Health and Brigham and Women’s Hospital in Boston, MA, and the Pennington Biomedical Research Center of Louisiana State University System in Baton Rouge, LA. Details of the study have been described previously (24). Briefly, this study included 811 overweight or obese individuals who were randomly assigned to one of four energy-reduced diets varying in macronutrient compositions of fat, protein, and carbohydrate to compare their effects on body weight change during a 2-year follow-up time. The targeted percentages of energy derived from fat, protein, and carbohydrates in the four diets were 1) 20, 15, and 65%; 2) 20, 25, and 55%; 3) 40, 15, and 45%; and 4) 40, 25, and 35%, respectively. Thus, two diets were low fat (20%), and the other two diets were high fat (40%); two diets were average protein (15%), and the other two diets were high protein (25%), which constituted a two-by-two factorial design. The low-fat/high-fat diets were the same as the high-carbohydrate/low-carbohydrate diets in the POUNDS Lost Study. The low-carbohydrate/high-fat diet was indicated by 35% or 45% carbohydrate/40% fat of energy; the high-carbohydrate/low-fat diet was indicated by 55% or 65% carbohydrate/20% fat of energy in this study. The study was approved by the human subjects committee at each institution and by a data and safety monitoring board appointed by the National Heart, Lung, and Blood Institute. All participants gave written informed consent.

In the current study, we investigated the data of 715 overweight or obese individuals (mean age 50.9 [SD 9.3] years) who had genotyping data on the *FGF21* variant rs838147 at the baseline examination. Of the study participants, 573 (80%) were white, 106 (15%) were African American, 25 (3%) were Hispanic, and 11 (22%) were Asian or other ethnic groups by self-report. WC data were available for 639 individuals at 6 months and for 541 at 2 years. For the assessment of body composition, a random

sample of ~50% of the total study participants were selected to undergo DEXA scans for fat mass and lean mass at baseline and after 6 months and 2 years of randomization (25). The DEXA scan was performed in 373 at the baseline examination, in 297 at 6 months, and in 211 at 2 years.

Measurements

Body weight and WC were measured at baseline, 6, 12, and 18 months, and 2 years. Height was measured at the baseline examination. BMI was calculated as weight in kilograms divided by the square of height in meters (kg/m^2). The DEXA scan was performed using a Hologic QDR 4500A (Hologic, Inc.) after an overnight fast. Total fat mass, total lean mass, whole-body total percentage fat mass, and trunk fat percentage were measured at baseline, 6 months, and 2 years of follow-up. Dietary intake was assessed in a random sample of 50% of the total participants by a review of 5-day diet records at baseline and by 24-h recall during a telephone interview on 3 non-consecutive days at 6 months and at 2 years to assess the adherence to the dietary intervention program.

Genotyping

DNA was extracted from the buffy coat fraction of centrifuged blood using the QIAamp Blood Kit (Qiagen). Our previously reported single-nucleotide polymorphism (SNP) in the *FGF21* locus rs838147 was genotyped (3). Genotyping was performed using the OpenArray SNP Genotyping System (BioTrove). The C allele of the rs838147 was associated with lower carbohydrate intake (3). The genotype success rate was 99%. The genotype frequencies were in Hardy-Weinberg equilibrium among all study participants or among two major (white and African American) ethnic groups ($P > 0.05$).

Statistical Analysis

General linear models for continuous variables and χ^2 test for categorical variables were performed for comparison of characteristics across the genotype at baseline examination. The primary outcomes were changes (Δ) in body weight, WC, and body composition assessed by DEXA (total fat, total lean, total fat mass percentage, and trunk fat percentage) among participants who remained in the trial. General linear models

were used to compare changes from baseline in these outcomes across genotype groups according to low- or high-carbohydrate diet group at 6-month and 2-year visits with an adjustment of age, sex, ethnicity, and baseline value for the respective outcome (model 1). We also analyzed data with BMI at the baseline examination being further included in the adjusted model (model 2). Additive genetic models were used in the analysis. To test potential gene–diet interactions, a genotype-by-diet product term (e.g., *FGF21* genotype × high-/low-carbohydrate diet group) was included in the models. We also performed similar analyses only among white participants. We performed an additional analysis using linear mixed model with time variable as a repeated measurement factor. We tested genetic associations with the trajectory of changes in WC and body composition over the 2-year intervention by including genotype–time interaction terms. Statistical analyses were performed with SAS 9.3 software (SAS Institute Inc.). The statistical significance was considered for $P < 0.05$.

RESULTS

The frequency of the *FGF21* rs838147 carbohydrate intake–decreasing C allele was 44.8% among the study participants. The genotype distribution did not differ by sex or the carbohydrate diet interventions, whereas a significant difference was observed across ethnicity ($P < 0.001$). No significant difference was found in age, BMI, body weight, WC, and body composition according to the *FGF21* rs838147 genotype (Table 1) at the baseline examination; however, the C allele was positively correlated with total energy intake ($P = 0.02$). We did not observe significant main associations of the *FGF21* genotype with changes in body weight, WC, or body composition (total fat, total lean, total fat mass percentage, or trunk fat percentage) during the 2-year intervention after adjustment for age, sex, ethnicity, BMI at baseline, low-/high-carbohydrate diet group, and baseline value for the respective outcome ($P > 0.05$ for all the outcomes, data not shown).

We found significant interactions between the genotype and low-/high-carbohydrate diet on 2-year changes in WC, total fat, total lean, total fat mass percentage, and trunk fat percentage

Table 1—Characteristics of study participants at the baseline examination according to the *FGF21* genetic variant rs838147

	TT <i>n</i> = 211	TC <i>n</i> = 367	CC <i>n</i> = 137	<i>P</i> value
Age, years	50.6 (9.1)	51.1 (9.4)	50.9 (9.4)	0.76
Male sex	75 (35.6)	147 (40.1)	57 (41.6)	0.44
Race or ethnic group				<0.001
White	150 (71.1)	306 (83.4)	117 (85.4)	
Black	50 (23.7)	42 (11.4)	14 (10.2)	
Hispanic or other	11 (5.2)	19 (5.2)	6 (4.4)	
Diet group				0.28
Low carbohydrate	114 (54.0)	173 (47.1)	68 (49.6)	—
High carbohydrate	97 (46.0)	194 (52.9)	69 (50.4)	—
Dietary intake per day*				
Energy, kcal	1,892 (545)	1,976 (555)	2,099 (617)	0.02
Protein, %	18.3 (2.9)	18.1 (3.6)	17.6 (2.9)	0.27
Fat, %	37.7 (6.3)	36.8 (5.9)	36.4 (5.9)	0.16
Carbohydrate, %	43.9 (7.3)	44.7 (7.8)	45.5 (7.9)	0.17
BMI, kg/m ²	32.6 (3.8)	32.8 (3.8)	32.5 (4.1)	0.997
Body weight, kg	92.2 (14.5)	93.7 (15.9)	94.1 (16.6)	0.24
WC, cm	102.3 (12.7)	104.4 (12.9)	103.8 (13.9)	0.19
Body composition data**				
Whole-body fat, kg	34.4 (7.9)	35.3 (7.6)	35.9 (8.5)	0.20
Whole-body lean, kg	58.7 (12.6)	61.0 (13.3)	61.4 (14.2)	0.14
Whole-body fat mass, %	37.1 (7.0)	36.9 (6.7)	37.1 (7.3)	0.96
Trunk fat, %	38.0 (6.1)	38.1 (5.8)	38.1 (6.5)	0.87

Data are mean (SD) or *n* (%). *Data for dietary intake per day were available for 366 individuals across the three genotype groups: TT, *n* = 111; TC, *n* = 194; and CC, *n* = 61. **Data for body composition were available for 373 individuals across the three genotype groups: TT, *n* = 113; TC, *n* = 189; and CC, *n* = 71.

($P_{interaction} = 0.049, 0.004, 0.003, 0.001,$ and 0.003 , respectively, in model 1) (Table 2). In response to the low-carbohydrate diet, an increasing number of the C allele of the *FGF21* variant was significantly associated with an increase in WC, total fat, total fat mass percentage, and trunk fat

percentage at 2 years. Conversely, carrying the C allele was negatively associated with changes in these outcomes in response to the high-carbohydrate diet (Table 2 and Fig. 1). Additional adjustment of BMI at the baseline in model 2 slightly attenuated the association, although

Table 2—Effect of the *FGF21* genetic variant on changes in body weight, WC, and body composition in response to low- or high-carbohydrate diet at 2 years of diet intervention

	Low carbohydrate		High carbohydrate		<i>P</i> _{interaction}
	β (SE)	<i>P</i>	β (SE)	<i>P</i>	
Model 1					
ΔBody weight, kg	1.46 (0.62)	0.02	−0.16 (0.64)	0.8	0.07
ΔWC, cm	1.22 (0.69)	0.08	−0.66 (0.66)	0.32	0.049
ΔTotal fat, g	1,861 (849)	0.03	−1,319 (781)	0.09	0.004
ΔTotal lean, g	837 (420)	0.049	−799 (410)	0.054	0.003
ΔTotal fat mass, %	1.25 (0.49)	0.01	−0.95 (0.50)	0.06	0.001
ΔTrunk fat, %	1.52 (0.65)	0.02	−1.12 (0.64)	0.08	0.003
Model 2					
ΔWC, cm	1.16 (0.68)	0.09	−0.44 (0.65)	0.5	0.09
ΔTotal fat, g	1,848 (854)	0.03	−1,221 (786)	0.12	0.006
ΔTotal lean, g	853 (421)	0.046	−806 (414)	0.054	0.003
ΔTotal fat mass, %	1.21 (0.49)	0.02	−0.94 (0.5)	0.06	0.002
ΔTrunk fat, %	1.35 (0.66)	0.04	−1.08 (0.64)	0.09	0.006

β represents changes in outcomes for the increasing number of C allele of the SNP rs838147. Bold values indicate statistical significance ($P < 0.05$). Model 1: age, sex, ethnicity, and variable of interest at the baseline examination. Model 2: model 1 plus BMI at the baseline examination.




Figure 1—Changes in WC (A), total fat mass percentage (B), and trunk fat percentage (C) according to the *FGF21* genetic variant rs838147 and low- or high-carbohydrate diet at 2 years of diet intervention (white bars, *FGF21* rs838147 TT genotype; gray bars, TC genotype; black bars, CC genotype). Data are means \pm SE values after adjustment for age, sex, ethnicity, and BMI at the baseline examination and value for the respective outcome traits at the baseline examination. CHO, carbohydrate.

P values for interactions between genotype and the low-/high-carbohydrate diet in 2-year changes of body composition remained significant. Further adjustment for total energy intake at baseline did not appreciably change the results (data not shown). When the analysis was performed only among white individuals, we observed fundamentally similar results with significant interactions for 2-year changes in total fat, total lean, total fat mass percentage, and trunk fat percentage (all $P_{\text{interaction}} < 0.05$ in model 2).

We also performed linear mixed models integrating measures at 6 months

and 2 years to assess the trajectory of genetic associations with the outcomes across the course of dietary intervention (Fig. 2). On the one hand, the gene–diet interaction patterns on WC were consistent at 6 months and 2 years, but participants regained WC during the 6 months and 2 years (Fig. 2A and B). On the other hand, we observed significant genotype–time interactions, particularly for changes in total fat mass percentage and trunk fat percentage among the low-carbohydrate diet group (Fig. 2C and E) and the high-carbohydrate diet group (Fig. 2D and F) over the 2-year trajectories. Results of genotype–time interactions were significant even after adjustment for age, sex, ethnicity, BMI, and the values for the respective outcome traits at the baseline examination; the genetic associations with improving in body fat composition appeared to be more pronounced at 2 years than at 6 months (Fig. 2C–F). Particularly, in the low-carbohydrate diet group, individuals without C allele (Fig. 2C and E, dotted line) continued to lose total fat mass and trunk fat from 6 months to 2 years.

CONCLUSIONS

In this trial, one of the largest randomized dietary intervention trials on weight loss, we found that the macronutrient intake–associated *FGF21* genotype significantly interacted with dietary carbohydrate/fat intake on changes in central adiposity and body composition. In response to the low-carbohydrate/high-fat diet, an increasing number of the carbohydrate intake–decreasing C allele of rs838147 was associated with less reduction in WC, whole-body fat, or trunk fat. Conversely, opposite genetic effects on these outcomes were observed in response to the high-carbohydrate/low-fat diet; carrying the C allele was associated with a greater reduction of WC, whole-body fat, and trunk fat.

Our findings are in line with the biological roles of FGF21 in regulating body adiposity and dietary intake. The *FGF21* gene encodes FGF21, a circulating hormone-like protein with pleiotropic metabolic actions, such as regulating glucose and fat metabolism, and effect on reducing body weight (26). On the one hand, elevated circulating levels of FGF21 have been associated with a variety of adiposity measures such as WC (12,14,16,17), BMI

(12–16), fat mass (13,16), and visceral fat (18,19), with obesity considered an FGF21-resistant state (20). On the other hand, several studies in rodents and humans reported that FGF21 levels were influenced by dietary intake of fat, carbohydrate, or protein (5,6,27–31). In two recent GWAS (3,4), we identified the genetic variants in the region of the *FGF21* gene that were associated with dietary macronutrient intakes, and rs838147 showed the strongest association with carbohydrate intake. In the current study, we observed significant interactions between the *FGF21* genotype and carbohydrate intake on adiposity measurements. The results from the present study and previous GWAS consistently indicate that FGF21 may play a role in regulating metabolisms of dietary carbohydrate. Because low-carbohydrate intake is usually accompanied by high-fat intake, we could not determine whether carbohydrate or fat would best explain our findings. Nonetheless, two recent studies found that FGF21 acted on the brain to regulate carbohydrate or sweet taste and did not affect response to fat taste preference (7,8), also suggesting that the *FGF21* genetic variants might primarily interact with dietary carbohydrate intake on adiposity measures.

In addition, we found that the genetic effects were opposite according to dietary carbohydrate intake on improving adiposity measurements. Such an opposite genetic effect could be partly explained by the “differential susceptibility hypothesis,” (32–34) a theory that suggests that genes may be conceptualized as “plastic,” because genetic risk can be modified by environmental factors, such as dietary factors. Some individuals might be more affected by environmental exposures because of genetic make-up in a for-better-and-for-worse manner, depending on the environment to which they are exposed (33). We observed that carriers of the carbohydrate-decreasing allele showed an opposite response to diet interventions varying in carbohydrate intake; we assume that high- or low-carbohydrate intake may differentially modulate the function or activity of the *FGF21* gene with the variant allele. Further studies are warranted to test such postulations.

We also observed significant gene–diet interactions, particularly on body fat composition and marginally on WC. Previous studies suggested that FGF21




Figure 2—Trajectories of WC (A and B), total body fat mass percentage (C and D), and trunk fat percentage (E and F) according to *FGF21* variant rs838147 in response to low- or high-carbohydrate diet during the 2-year intervention assessment (black circle and solid line, CC genotype; gray circle and gray solid line, TC genotype; white circle and dotted line, TT genotype). Data are mean \pm SE after adjustment for age, sex, ethnicity, BMI at the baseline examination, and value for the respective outcome traits at the baseline examination. *P* for interaction (genotype \times time) after adjustment for age, sex, ethnicity, and BMI at the baseline examination: *P* > 0.05 (not significant) for A and B; *P* < 0.001 for C, D, E, and F. *P* for interaction (genotype \times time) after adjustment for age, sex, ethnicity, BMI, and value for the respective outcome traits at the baseline examination: *P* > 0.05 (not significant) for A and B; *P* = 0.006 for C; *P* = 0.01 for D and E; and *P* = 0.02 for F.

may act directly on adipose tissue and that the weight-reducing effect of *FGF21* may be partially mediated by induction of thermogenesis in adipose tissue and browning of white adipose tissue (11,26,35). A study has demonstrated that *FGF21* levels were slightly better correlated with WC than with BMI and that WC was significantly positively associated with serum *FGF21* levels even after adjustment for BMI (12).

Plasma concentrations of *FGF21* were also reported to be positively associated with both BMI and fat mass, whereas only body fat mass was predictive of plasma *FGF21* concentrations when the analysis adjusted for covariates (13). Taken together, these data suggest that the *FGF21* genotype may particularly affect certain body fat composition, independent of overall body weight. Whether changes in energy expenditure

contribute to explaining our results would need to be further investigated.

Intriguingly, our analysis using the linear mixed models indicated significant genotype–time interaction, supporting that the gene–diet interaction became stronger at 2 years than at 6 months. Participants in the POUNDS Lost trial regained body weight from 6 months to 2 years (24). Nonetheless, we found that carriers without the C allele in the low-carbohydrate/high-fat diet group continued to lose total body fat and trunk fat even though they regained body weight and WC from 6 months to 2 years. Although the mechanisms underlying such observations remained unclear, our data suggest that different pathways might be involved in linking *FGF21* to overall body weight and specific body fat composition. Because *FGF21* has diverse metabolic functions in multiple target organs, including liver and brain (26,36–38), further investigations are warranted to verify our postulations.

To the best of our knowledge, this is the first study to show significant interactions between the macronutrient intake–associated *FGF21* genetic variation and dietary carbohydrate/fat intake on improvement of body composition and central obesity in a large and long-term randomized trial among overweight or obese individuals. Growing evidence shows that *FGF21* may be a potential for the treatment of obesity-related metabolic diseases (10,37–39); our study provides novel data to support potential precision dietary interventions considering the *FGF21* genotype.

Nonetheless, several limitations of this study should also be considered. We did not measure circulating *FGF21* concentrations in this study, which limited our ability to explore potential underlying mechanisms. In addition, 80% of our study participants were white, and the genotype distribution differed across ethnicities. Our subgroup analysis in whites showed similar results; nevertheless, whether our findings are generalizable to other ethnicities needs to be further investigated.

In conclusion, our study showed that dietary carbohydrate/fat intake modified the effect of the *FGF21* genotype on changes in central adiposity and body fat composition among overweight or obese individuals during a 2-year dietary intervention. Our findings suggest that a high-carbohydrate/low-fat diet may be beneficial for overweight

or obese individuals who carry the carbohydrate intake–decreasing allele of the *FGF21* variant to improve body fat composition and abdominal obesity.

Acknowledgments. The authors thank all of the participants in the study for their dedication and contribution to the research.

Funding. The study is supported by National Institutes of Health grants from the National Heart, Lung, and Blood Institute (HL-071981, HL-034594, HL-126024), the National Institute of Diabetes and Digestive and Kidney Diseases (DK-091718, DK-100383, DK-078616), the Boston Obesity Nutrition Research Center (DK-46200), and United States–Israel Binational Science Foundation Grant 2011036. Y.H. is a recipient of a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science. L.Q. is a recipient of the American Heart Association Scientist Development Award (0730094N). The sponsors had no role in the design or conduct of the study.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. Y.H. contributed to the study concept and design, analysis and interpretation of data, drafting and revising the manuscript, statistical analysis, and study supervision. W.M. and T.H. contributed to analysis and interpretation of data and to drafting and revising the manuscript. T.W. and Y.Z. contributed to interpretation of data. S.R.S., G.A.B., and F.M.S. contributed to acquisition of data, interpretation of data, and drafting and revising the manuscript. L.Q. contributed to the study concept and design, acquisition of data, analysis and interpretation of data, drafting and revising the manuscript, statistical analysis, funding, and study supervision. All authors were involved in the writing and revising of the manuscript and approved the final version. L.Q. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

References

- Hooper L, Abdelhamid A, Moore HJ, Douthwaite W, Skeaff CM, Summerbell CD. Effect of reducing total fat intake on body weight: systematic review and meta-analysis of randomised controlled trials and cohort studies. *BMJ* 2012;345:e7666
- Tobias DK, Chen M, Manson JE, Ludwig DS, Willett W, Hu FB. Effect of low-fat diet interventions versus other diet interventions on long-term weight change in adults: a systematic review and meta-analysis. *Lancet Diabetes Endocrinol* 2015;3:968–979
- Tanaka T, Ngwa JS, van Rooij FJ, et al. Genome-wide meta-analysis of observational studies shows common genetic variants associated with macronutrient intake. *Am J Clin Nutr* 2013;97:1395–1402
- Chu AY, Workalemahu T, Paynter NP, et al.; CHARGE Nutrition Working Group; DietGen Consortium. Novel locus including *FGF21* is associated with dietary macronutrient intake. *Hum Mol Genet* 2013;22:1895–1902
- Dushay JR, Toschi E, Mitten EK, Fisher FM, Herman MA, Maratos-Flier E. Fructose ingestion acutely stimulates circulating *FGF21* levels in humans. *Mol Metab* 2014;4:51–57
- Sánchez J, Palou A, Picó C. Response to carbohydrate and fat refeeding in the expression of genes involved in nutrient partitioning and metabolism: striking effects on fibroblast growth factor-21 induction. *Endocrinology* 2009;150:5341–5350
- von Holstein-Rathlou S, BonDurant LD, Peltekian L, et al. *FGF21* mediates endocrine control of simple sugar intake and sweet taste preference by the liver. *Cell Metab* 2016;23:335–343
- Talukdar S, Owen BM, Song P, et al. *FGF21* regulates sweet and alcohol preference. *Cell Metab* 2016;23:344–349
- Adams AC, Gimeno RE. The sweetest thing: regulation of macronutrient preference by *FGF21*. *Cell Metab* 2016;23:227–228
- Degriolamo C, Sabbà C, Moschetta A. Therapeutic potential of the endocrine fibroblast growth factors *FGF19*, *FGF21* and *FGF23*. *Nat Rev Drug Discov* 2016;15:51–69
- Cantó C, Auwerx J. Cell biology. *FGF21* takes a fat bite. *Science* 2012;336:675–676
- Zhang X, Yeung DC, Karpisek M, et al. Serum *FGF21* levels are increased in obesity and are independently associated with the metabolic syndrome in humans. *Diabetes* 2008;57:1246–1253
- Tan BK, Hallschmid M, Adya R, Kern W, Lehnert H, Randeve HS. Fibroblast growth factor 21 (*FGF21*) in human cerebrospinal fluid: relationship with plasma *FGF21* and body adiposity. *Diabetes* 2011;60:2758–2762
- Cuevas-Ramos D, Almada-Valdes P, Gómez-Pérez FJ, et al. Daily physical activity, fasting glucose, uric acid, and body mass index are independent factors associated with serum fibroblast growth factor 21 levels. *Eur J Endocrinol* 2010;163:469–477
- Reinehr T, Woelfle J, Wunsch R, Roth CL. Fibroblast growth factor 21 (*FGF-21*) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. *J Clin Endocrinol Metab* 2012;97:2143–2150
- Olszanecka-Glinianowicz M, Madej P, Wdowczyk M, Owczarek A, Chudek J. Circulating *FGF21* levels are related to nutritional status and metabolic but not hormonal disturbances in polycystic ovary syndrome. *Eur J Endocrinol* 2015;172:173–179
- Mai K, Schwarz F, Bobbert T, et al. Relation between fibroblast growth factor-21, adiposity, metabolism, and weight reduction. *Metabolism* 2011;60:306–311
- Giannini C, Feldstein AE, Santoro N, et al. Circulating levels of *FGF-21* in obese youth: associations with liver fat content and markers of liver damage. *J Clin Endocrinol Metab* 2013;98:2993–3000
- Taniguchi H, Tanisawa K, Sun X, et al. Cardiorespiratory fitness and visceral fat are key determinants of serum fibroblast growth factor 21 concentration in Japanese men. *J Clin Endocrinol Metab* 2014;99:E1877–E1884
- Fisher FM, Chui PC, Antonellis PJ, et al. Obesity is a fibroblast growth factor 21 (*FGF21*)-resistant state. *Diabetes* 2010;59:2781–2789
- Fazeli PK, Lun M, Kim SM, et al. *FGF21* and the late adaptive response to starvation in humans. *J Clin Invest* 2015;125:4601–4611
- Hooper L, Abdelhamid A, Bunn D, Brown T, Summerbell CD, Skeaff CM. Effects of total fat intake on body weight. *Cochrane Database Syst Rev* 2015;8:CD011834
- Johnston BC, Kanter S, Bandayrel K, et al. Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis. *JAMA* 2014;312:923–933
- Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. *N Engl J Med* 2009;360:859–873
- de Souza RJ, Bray GA, Carey VJ, et al. Effects of 4 weight-loss diets differing in fat, protein, and carbohydrate on fat mass, lean mass, visceral adipose tissue, and hepatic fat: results from the POUNDS LOST trial. *Am J Clin Nutr* 2012;95:614–625
- Gimeno RE, Moller DE. *FGF21*-based pharmacotherapy—potential utility for metabolic disorders. *Trends Endocrinol Metab* 2014;25:303–311
- Wall CE, Whyte J, Suh JM, et al. High-fat diet and *FGF21* cooperatively promote aerobic thermogenesis in mtDNA mutator mice. *Proc Natl Acad Sci U S A* 2015;112:8714–8719
- Müller TD, Tschöp MH. Play down protein to play up metabolism? *J Clin Invest* 2014;124:3691–3693
- Laeger T, Henagan TM, Albarado DC, et al. *FGF21* is an endocrine signal of protein restriction. *J Clin Invest* 2014;124:3913–3922
- Nygaard EB, Møller CL, Kievit P, Grove KL, Andersen B. Increased fibroblast growth factor 21 expression in high-fat diet-sensitive non-human primates (*Macaca mulatta*). *Int J Obes* 2014;38:183–191
- Vienberg SG, Brøns C, Nilsson E, Astrup A, Vaag A, Andersen B. Impact of short-term high-fat feeding and insulin-stimulated *FGF21* levels in subjects with low birth weight and controls. *Eur J Endocrinol* 2012;167:49–57
- Belsky J, Jonassaint C, Pluess M, Stanton M, Brummett B, Williams R. Vulnerability genes or plasticity genes? *Mol Psychiatry* 2009;14:746–754
- Belsky J, Hartman S. Gene-environment interaction in evolutionary perspective: differential susceptibility to environmental influences. *World Psychiatry* 2014;13:87–89
- Belsky J, Pluess M. Beyond diathesis stress: differential susceptibility to environmental influences. *Psychol Bull* 2009;135:885–908
- Adams AC, Yang C, Coskun T, et al. The breadth of *FGF21*'s metabolic actions are governed by *FGFR1* in adipose tissue. *Mol Metab* 2012;2:31–37
- Domouzoglou EM, Naka KK, Vlahos AP, et al. Fibroblast growth factors in cardiovascular disease: the emerging role of *FGF21*. *Am J Physiol Heart Circ Physiol* 2015;309:H1029–H1038
- Fisher FM, Maratos-Flier E. Understanding the physiology of *FGF21*. *Annu Rev Physiol* 2016;78:223–241
- Zhang J, Li Y. Fibroblast growth factor 21 analogs for treating metabolic disorders. *Front Endocrinol (Lausanne)* 2015;6:168
- Zhang F, Yu L, Lin X, et al. Minireview: roles of fibroblast growth factors 19 and 21 in metabolic regulation and chronic diseases. *Mol Endocrinol* 2015;29:1400–1413